Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 16;10:238. doi: 10.1038/s41398-020-00923-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Compared to vehicle (Veh, square), repeated dulaglutide treatment (Dul, triangle) decreased ethanol intake in female rats during active treatment (session 1–27). After treatment discontinuation (session 28–33, area marked with grey) ethanol intake did not differ between the dulaglutide and vehicle groups. b Dulaglutide treatment reduced ethanol preference, however this effect did not persist after treatment termination. Dulaglutide did not affect (c) water or (d) total fluid intake. e Dulaglutide decreased food intake, but this difference was not evident after treatment termination. f Dulaglutide treatment reduced the body weight gain. This overall lower body weight gain sustained post-treatment. ^#P < 0.05: treatment effects after repeated measures two-way ANOVA, ^•P < 0.05, ^••P < 0.001, ^•••P < 0.001: Bonferroni post-hoc analysis. Session 0 represent the baseline values.